Simponi Aria (Golimumab) for Rheumatoid Arthritis | myRAteam

Connect with others who understand.

sign up Log in
About myRAteam
Powered By

Simponi Aria is a prescription drug approved by the U.S. Food and Drug Administration (FDA ) to treat adults with moderate to severe rheumatoid arthritis. Simponi Aria is approved to be used in combination with methotrexate. Simponi Aria is also referred to by its drug name, golimumab.

Simponi Aria is considered a biologic disease-modifying antirheumatic drug (DMARD). It is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Simponi Aria is believed to work by binding to a cellular chemical messenger attaching to tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks. This prevents the messenger from signaling the immune system to attack the body’s connective tissues.

How do I take it?
Prescribing information states that Simponi Aria is administered as an intravenous infusion (slow injection into your vein) by a health care professional every 8 weeks after initial loading doses.

Side effects
The FDA-approved label for Simponi Aria lists common side effects including respiratory tract infections, viral infections, elevated liver enzymes, low white blood cell counts, bronchitis, high blood pressure, and rash.

Rare but serious side effects listed for Simponi include severe infections, hepatitis B virus reactivation, increased risk for lymphoma and other cancers, heart failure, nerve damage, lupus-like syndrome, and severe allergic reactions.

For more details about this treatment, visit:

Simponi Aria — Janssen

Golimumab for Infusion (Simponi Aria) — Johns Hopkins Arthritis Center

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in